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Abstract
Background: Xenotropic murine leukaemia virus-related virus (XMRV) is a recently discovered human gammaretrovirus with
yet unknown prevalence and transmission route(s). Its presence in prostate stromal fibroblasts and prostatic secretions
suggests that XMRV might be sexually transmitted. We chose to study a compartment closely connected to the prostate, a
location where XMRV was detected in independent studies. Seminal plasma samples from HIV-1 infected men were
examined as they have an increased probability of acquiring sexually transmitted pathogens.
Methodology/Principal Findings: We studied the prevalence of XMRV in 93 seminal plasma samples of 54 HIV-1 infected
men living in The Netherlands with a nested PCR amplification specifically targeting the XMRV gag gene. As a control for the
presence and integrity of retrovirus particles, HIV-1 was amplified from the same samples with a PCR amplification targeting
the env gene of the virus, or HIV-1 was quantified with a real-time PCR amplifying part of the pol gene.
Conclusions/Significance: Although HIV-1 was amplified from 25% of the seminal plasma samples, no XMRV was detected,
suggesting that either the prevalence of XMRV is very low in The Netherlands, or that XMRV is not naturally present in the
seminal plasma.
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Introduction
XMRV is the first gammaretrovirus known to infect humans
and it has been discovered only recently. Gammaretroviruses are
relatively simple retroviruses that are not known to encode
accessory genes. XMRV is related to retroviruses from mice and
was detected in blood from chronic fatigue syndrome (CFS)
patients and healthy controls [1] and in prostate specimens from
patients with prostate cancer [2–5]. These findings may suggest a
transmission route by blood (products) or sexual transmission. The
incidence of XMRV infection in patient and control groups varies
from 0 to 67%, but has not been investigated systematically in the
general population. Higher incidences were often reported from
the USA compared to Europe [1–11], suggestive of regional
differences. A local outbreak of CFS in the USA in 1984 was
postulated to be associated with XMRV [1,8].
XMRV can infect a wide range of cell types and host species in
vitro, including human hematopoietic cell lines and prostrate
stromal fibroblasts [12]. Furthermore, XMRV is infectious both as
a cell–free and as a cell-associated virus [1] and replicates to high
titres in prostate carcinoma cell lines [13]. In addition, XMRV has
been found in prostatic secretions from men with prostate cancer
[14], suggesting the possibility of sexual transmission.
In this study, we have investigated the presence of XMRV and
the possibility of sexual transmission of this novel human retrovirus
by screening for XMRV in seminal plasma from two groups of
HIV-1 infected men, e.g. men having sex with men (MSM, n=29)
and HIV-1 infected heterosexual men from couples seeking
fertility treatment (n=25). HIV-1 infected men were examined in
this study as they have an increased probability of acquiring other
sexually transmitted pathogens, and because HIV-1 is known to
upregulate expression of other retroviruses, especially endogenous
retroviruses [15]. As such, they comprise an ideal population to
examine the presence of XMRV in a compartment closely
connected to the prostate, the only location where XMRV was
detected in independent studies, and secondly, to test the
hypothesis of sexual XMRV transmission. Furthermore, the
detection of HIV-1 can serve as a control for the degradation of
retroviral particles in the seminal plasma samples.
Methods
Objectives
The objective of this study is to investigate the presence of
XMRV nucleic acid in seminal plasma. We hypothesize that
XMRV could be present in this compartment, as it has been
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samples from HIV-1 infected men, as they have a higher chance of
contracting sexually transmitted pathogens than non-HIV-1
infected men. In addition, the concurrent detection of HIV-1 in
the seminal plasma samples can serve as a control for the integrity
of retroviral nucleic acid. For 39 patients, a sample from another
time-point was available. As virus shedding might not be
continuous, those samples were also tested. So, a total of 93
samples from 54 patients were analysed for the presence of
XMRV.
Participants
Seminal plasma was separated from semen collected from either
MSM participating in a study examining the semen quality in
HIV-1 infected men [16], or from HIV-1 infected heterosexual
men undergoing sperm-washing procedures for fertility treatment
(for a review of this topic, see [17]). Patients of the latter group
were mainly HIV-1 infected by heterosexual contacts, 2 patients
were haemophiliacs infected by blood products, and one patient
had injected drugs in the past. Patients of the MSM group were
not treated with antiretroviral therapy, before or at the sampling
moment, while most men in the second group were treated with
diverse regimens of antiretroviral drugs. Patient characteristics are
summarized in Table 1.
Ethics
The MSM were enrolled in a study protocol on the effect of
HAART on semen quality. The study was approved by the
Institutional Review Board (IRB) of the Academic Medical Centre
(AMC) of the University of Amsterdam and all patients gave
written informed consent for their semen to be used in general
research. Since 2003, the Academic Medical Centre of the
University of Amsterdam offers intrauterine insemination (IUI) of
HIV-1- serodiscordant couples with a HIV-1 positive man and
proven HIV-1 negative woman, and patients are informed that
there is no 100% guarantee that infection with HIV-1 will not take
place during treatment. All patients sign informed consent.
No specific approval by the IRB of the AMC for the XMRV
study was needed in The Netherlands, because the body materials
for this study were collected under medical treatment, and can be
used for further scientific research when the patients have given
consent and samples are analysed anonymously, as was the case
here (Code of Conduct as implemented by the Committee on
Regulation of Research COREON of the Netherlands Epidemi-
ological Society and the Dutch Federation of Biomedical Scientific
Societies that is followed by the IRB of the AMC).
Nucleic acid isolation
Semen samples were diluted 1:1 in Hanks balanced salt solution
(HBSS; Sigma, St. Louis, MO, USA) and separated by centri-
fugation at 350 g for 10 minutes. The supernatant (= seminal
plasma) was stored directly at 280uC, and thawed only once (for
this study). Total nucleic acid was extracted from 200 ml of the
seminal plasma samples with a method using silica and guanidium
thiocyanate [18]. MS2 RNA was added before the extraction,
reverse transcribed and subsequently PCR amplified, as an
extraction and PCR control. One tenth of the total isolated
nucleic acid was reverse transcribed with Superscript III (Invitro-
gen Corporation, Carlsbad, CA, USA) before performing PCR
reactions, such that both viral DNA and RNA will be amplified.
HIV-1 detection
HIV-1 RNA in seminal plasma was detected with a single PCR
amplifying a 723 nt fragment of the env gene. PCR primers for
env gene detection were ED31 [19] and 59 ATGGGAGGGG-
CATACATTGCT 39 and PCR reactions were performed with
the Superscript
TM III One-step RT-PCR System with PlatinumH
Taq High Fidelity (Invitrogen Corporation Carlsbad, Calif., USA).
Amplification was performed for 45 cycles, each cycle involved
three steps: 15 sec at 94uC, 30 sec at 55uC, and 1 min at 68uC,
plus a final extension of 5 min at 68uC. In addition, seminal
plasma samples that were positive for HIV were quantified with a
real-time PCR targeting a fragment of the pol gene as described
previously [20]. In both assays the limit of detection was 50 copies
HIV-1 RNA/ml. HIV-1 blood plasma viral load measurements
were done at the Laboratory of Clinical Virology at the AMC
(Amsterdam, The Netherlands) with the Versant HIV-1 RNA 3.0
assay (Bayer Diagnostics Division Tarrytown, N.Y.).
XMRV detection
To detect XMRV sequences in the seminal plasma samples, a
reverse-transcriptase (RT) reaction was performed with Super-
Script III (Invitrogen, Carlsbad, CA, USA) of 1/10 of the isolated
nucleic acid, corresponding to 10 ml of the undiluted seminal
plasma sample and the downstream outer primer used in the
subsequent first PCR reaction; 59 GCCGCCTCTTCTTCATT-
GTTCTC 39 [1]. A first PCR amplification was performed in a
total reaction volume of 50 mL with 1U Taq DNA polymerase
Table 1. Characteristics of patients and virus detection results.
Homosexual men Heterosexual men All men
No. of patients 29 25 54
Mean age (range) 42.4 (32–66) 37.8 (29–46) 40.1
Origin* Dutch: 21
Non-Dutch: 2
Unknown: 6
Dutch: 18
Non-Dutch: 7
Dutch: 39 (72%)
Non-Dutch: 9 (17%)
Unknown: 6 (11%)
No. of seminal samples tested 30 63 93
Blood plasma HIV-1.50
copies/ml
28/30 5/63 33/93 (35%)
Seminal plasma HIV-1.50
copies/ml
20/30 3/63 23/93 (25%)
XMRV+ 0/30 0/63 0/93 (0%)
*All men are currently living in The Netherlands.
doi:10.1371/journal.pone.0012040.t001
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primers described by Lombardi et al. [1]: 59ATCAGTTAACC-
TACCCGAGTCGGAC 39 and 5 GCCGCCTCTTCTTCATT-
GTTCTC 39, amplifying a fragment of 730 nt of XMRV gag. A
second PCR in a total reaction volume of 25 mL containing 5 mL
of the first PCR reaction was done with the nested primers
59GTCTTTAAGTGTTCTCGAGA 39 and 59 GGCTTAGGA-
GGTTTGGACTT 39, amplifying a fragment of 450 nt of the
gag gene of XMRV. Amplification was done for 40 cycles in the
first PCR and 30 cycles for the second PCR. Each cycle involved
three steps: 1 min at 95uC, 1 min at 55uC, and 2 min at 72uC,
plus a final extension of 10 min at 72uC. Samples were tested
twice. The detection limit of the XMRV-gag PCR is 5–10 copies
input in the PCR reaction, and was assessed with the 730 nt
XMRV gag fragment obtained from the 22Rv1 cell line. This
fragment was cloned into the TOPO TA vector (Invitrogen,
Carlsbad, CA, USA). Gag clones were confirmed by sequencing.
Plasmid DNA was isolated, digested with Eco RI and fragments
were excised from a 1.5% agarose gel and eluted with the
NucleoSpin Extract II system (Macherey-Nagel, Dueren, Ger-
many). Fragment concentration was determined with the
Qubit
TM Quantitation Platform following the manufacturers’
instructions (Invitrogen, Carlsbad, CA, USA); copy numbers were
subsequently calculated. As a positive PCR control, we used
diluted total nucleic acid extracted from the prostate carcinoma
cell line 22Rv1, containing approximately 10 copies of integrated
XMRV DNA and producing viral RNA, in each PCR reaction
series.
Results
Ninety-three seminal plasma samples of 54 HIV-1 infected men,
29 infected by homosexual contacts and 25 infected otherwise, but
mainly heterosexually, were analysed for the presence of HIV-1
and XMRV. Fig. 1 shows the sensitivity of our nested XMRV gag-
PCR that can detect up to 5 copies of an XMRV-gag fragment
spiked in seminal plasma (panel A), but did not amplify any
XMRV-gag fragments in any patient samples (5 representative
patient samples are shown in panel B). In total, in 67% of seminal
plasma samples from MSM HIV-1 nucleic acid could be detected,
but none of them contained XMRV (Table 1). Five percent of the
seminal plasma samples from heterosexual men contained HIV-1,
but XMRV nucleic acid was never amplified (Table 1).
In conclusion, no XMRV RNA or DNA was detected in 93
seminal plasma samples of 54 HIV-1 infected men, a group with
an increased incidence of sexually transmitted diseases.
Discussion
The fact that we cannot detect XMRV in the seminal plasma of
54 men, could argue against the presence of XMRV in that
compartment and subsequently against sexual transmission of this
novel retrovirus, although we can not exclude the possibility that
XMRV does not penetrate the seminal plasma. Alternatively, the
absence of XMRV could indicate a low prevalence of the virus in
Northern Europe. In prostate cancer studies from Germany, the
virus was either not detected at all (in 589 tumour samples [6]), or
the prevalence was very low: 1/105 samples from prostate cancer
Figure 1. PCR-amplification of XMRV-gag fragments. PCR fragments were analysed on a 2% agarose-gel. (A) Using a cloned XMRV-gag
fragment, the sensitivity of our nested PCR reaction amplifying a fragment of 450 bp was determined to be around 5 copies input DNA spiked in
XMRV- negative seminal plasma (left panel). High input copy numbers resulted in high molecular weight products that are most likely the result of
trapping of excess DNA. MS2 RNA was used as an internal control during the extraction and reverse-transcription reaction, and was amplified in all
cases (right panel). (B) PCR-results for five representative patient seminal plasma samples where no XMRV-gag fragments were amplified are shown
(left panel). The MS2 internal control fragment of 225 bp was always amplified (right panel), suggesting that no degradation of nucleic acid during
extraction, or inhibition during amplification, had occurred.
doi:10.1371/journal.pone.0012040.g001
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tested positive for XMRV in another German study [3]. In
contrast, in an initial study from the USA, XMRV DNA was
found in 8/19 (42%) prostate cancer tissues [2]. In a second North
American study 6% of 334 prostate cancer specimens tested
XMRV DNA positive, with 23% of these samples expressing
XMRV proteins [4]. Also, in a third study, XMRV DNA was
found in blood samples from 3.7% of healthy people living in the
USA, and in an astonishing 67% of patients with CFS [1]. The
latter patients were from a local outbreak of CFS in Incline, Lake
Tahoe, USA, with an already suspected viral aetiology. The
detection of XMRV in such large numbers could indicate that the
virus is spreading in humans and causes local outbreaks [8]. It
would be interesting to examine blood and seminal secretions from
people living in the Lake Tahoe area for XMRV, although a virus
that can infect many people in a short period is less likely to be
transmitted only sexually. In line with this, a recent paper reported
the detection of XMRV sequences in respiratory secretions,
suggesting a possible transmission route by coughing or sneezing
[9]. No XMRV was found in (sporadic) CFS patients or healthy
controls in three studies from Great Britain and the Netherlands
[7,8,21], also arguing against a high prevalence of the virus in
Europe.
Limitations
None of the homosexual men studied here were treated with
anti-retroviral drugs, but from the heterosexual men, an argument
for not detecting XMRV could be that 90% of them are taking
antiretroviral therapy, resulting in HIV-1 viral RNA levels in
blood plasma below the detection limit. Although protease
inhibitors specifically designed to inhibit HIV-encoded protease
do not affect XMRV infection and replication, nor do non-
nucleoside reverse-transcriptase inhibitors (NNRTI), XMRV is
susceptible to the nucleoside reverse-transcriptase inhibitors
(NRTI) azidothymidine (AZT) but not tenofovir in one study
[22], or to AZT and tenofovir in another study [23]. In our
heterosexual patient group, at least 4 patients were taking drug
regimens containing AZT, which could obstruct the detection of
XMRV. Tenofovir use, however, was not documented. Also,
XMRV was found to be susceptible to the integrase inhibitor
raltegravir [24]. Raltegravir was approved by the U.S. Food and
Drug Administration (FDA) in 2007. As the patients were sampled
well before that time, raltegravir use is not an explanation for not
detecting XMRV.
A second alternative for not detecting XMRV in seminal
plasma could be that the virus is cell-associated, and might be
found in semen, but not in seminal plasma. Then, sexual
transmission of the virus could still be possible. Or, it could be
that XMRV is not excreted at all by the prostate.
A third alternative for the absence of XMRV in our samples
could be that the XMRV found in other studies is an inadvertent
laboratory contaminant, which has been reported before for other
viruses, including another MuLV-related virus [25].
Taken together our results suggest that either XMRV has a low
prevalence in this mainly Dutch patient group, as it cannot be
found in seminal plasma of 54 HIV-1 infected men, a group with
an increased possibility of acquiring sexually transmitted patho-
gens, or that it is not naturally present in the seminal plasma.
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